

Virtual reality minimizes anxiety in children and adolescents with life-limiting conditions: a randomized control trial

| | | |
|--|---|--|
| Submission date 03/01/2025 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 08/01/2025 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 08/01/2025 | Condition category Mental and Behavioural Disorders | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |
| | | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

Children and adolescents with life-limiting conditions (LLC) often face frequent hospital visits, unpleasant medical procedures, and treatment side effects. These experiences can cause high levels of anxiety and distress. To address this, there is an increasing focus on psychological interventions, including modern technologies and non-drug approaches.

One promising method is virtual reality (VR), which creates a computer-generated environment that makes users feel as though they are physically present in that space. While VR is a relatively new approach with limited research, early evidence shows it can reduce stress, anxiety, and pain in children. This study aims to evaluate how effective VR is and how it can help severely ill children in hospital settings.

Who can participate?

Children aged 10 to 17 years who have life-limiting conditions and are receiving treatment at University Hospital Motol in the Czech Republic

What does the study involve?

Children participating in the study are randomly placed into one of two groups while at University Hospital Motol's hemato-oncology or gastroenterology unit.

Group 1: Participants have two VR sessions, spaced 14 to 42 days apart.

Group 2: Participants have a video session first, followed by a VR session for the second session. Before and after each session, participants answer questions about their anxiety, fear, and pain levels. After the VR session, they are also asked about symptoms of cybersickness, as well as their level of engagement, enjoyment, and immersion in the VR environment.

What are the possible benefits and risks of participating?

Participants may experience immediate reductions in anxiety and enjoy a fun and novel experience. In the long term, the study has the potential to improve the quality of life for severely ill children.

The main risk is potential cybersickness, which can cause symptoms like dizziness or nausea. To minimize this, a trained researcher will be present throughout the session to monitor the child's condition and provide support if needed.

Where is the study run from?

The study is managed by Charles University (1st, 2nd, and 3rd Faculty of Medicine), the National Institute of Mental Health, and University Hospital Motol, where the research takes place.

When is the study starting and how long is it expected to run for?

April 2022 to December 2023

Who is funding the study?

Vlček Family Foundation (NRV) (Czech Republic)

Who is the main contact?

Anna Zubkova, anna.zubkova1250@gmail.com, anna.zubkova@nudz.cz

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Ms Anna Zubková

ORCID ID

<https://orcid.org/0000-0002-6633-9395>

Contact details

Křížkovského 2727/9

Praha 3

Czech Republic

13000

+420 (0)608555964

anna.zubkova@nudz.cz

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

EK - 667/22

Study information

Scientific Title

The use of experiential virtual reality to minimize anxiety in children with life-limiting conditions: a randomized control trial

Study objectives

Experiential virtual reality is a feasible, acceptable, and effective method for alleviating anxiety in children with life-limiting conditions.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 15/06/2022, Ethics Committee for Multi-Centric Clinical Trials of the University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague (V úvalu 84, Prague, 150 06, Czech Republic; +420 (0)224 431 195; etickakomise@fnmotol.cz), ref: EK - 667/22

Study design

Single-centre interventional randomized control trial

Primary study design

Interventional

Study type(s)

Efficacy

Health condition(s) or problem(s) studied

Anxiety in pediatric patients with life-limiting conditions (hematology-oncology and gastroenterology outpatient clinics)

Interventions

The study employs a randomized controlled trial design, integrating both between-subjects and within-subjects approaches to evaluate the feasibility and effectiveness of a virtual reality distraction intervention (VR-DT) in comparison to a video-based distraction method. Participants are randomized using simple randomization by drawing names from an envelope. The intervention is administered during chemotherapy or infusion sessions. Virtual reality is used for 10 to 15 minutes, with an additional 8 minutes allocated for pre-session questionnaires and 6 minutes for post-session questionnaires, resulting in a total session duration of 35 minutes. During the VR experience, the researcher assists with the VR equipment (Meta Quest 2 headset), addresses participant queries, and provides support in managing any stress or discomfort in emergency situations. In the control group, the same procedure is followed, but a video intervention is used instead, delivered via an Apple iPad. A total of 18 children and adolescents are recruited through opportunity sampling and are randomly assigned to one of two groups. The experimental group (n = 10) receives two VR intervention sessions, spaced 14 to 42 days apart, according to their individual medical schedules, while the control group (n = 8) first participates in a video intervention, followed by a VR intervention in the second session. Measurements are taken before and after the interventions to assess anxiety, pain, fear, cyber sickness, and subjective feedback of the participants, using standardized scales and questionnaires.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Experiential Virtual Reality (using headset MetaQuest 2)

Primary outcome(s)

Anxiety measured using the "Scale Measuring Anxiety in Children - Short Version" at pre-intervention and post-intervention stages for both VR and video groups. The same procedure was followed in both sessions.

Key secondary outcome(s)

1. Fear measured using the Children Fear Scale (CFS) and Child Medical Fear Scale (CMFS) at pre-intervention and post-intervention stages for both VR and video groups. The same procedure was followed in both sessions.
2. Pain measured using the Wong-Baker Faces Visual Analog Scale (VAS) at pre-intervention and post-intervention stages for both VR and video groups. The same procedure was followed in both sessions.
3. Cybersickness measured using the Simulation Sickness Questionnaire (SSQ) at the post-intervention stage exclusively for the VR group. The same procedure was followed in both sessions.
4. Engagement, enjoyment, and immersion measured using a structured 4-point scale (0: not at all – 3: significantly) at the post-intervention stage for both VR and video groups. The same procedure was followed in both sessions.
5. Desire for distraction and perceived efficacy measured using a 5-point Likert scale (1: strongly agree – 5: strongly disagree) at the post-intervention stage for both VR and video groups. The same procedure was followed in both sessions.

Completion date

11/12/2023

Eligibility**Key inclusion criteria**

1. Sufficient level of contact with the environment and ability to cooperate
2. Fluency in Czech for both children and parents
3. Diagnosis of a life-threatening or life-limiting illness according to the internationally accepted list of palliative relevant diagnoses (Fraser et al., 2020)
4. Pediatric patients treated at University Hospital Motol

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

10 years

Upper age limit

17 years

Sex

All

Total final enrolment

18

Key exclusion criteria

1. Age below 10 or above 18 years
2. Unstable health status
3. Inability to speak Czech
4. Absence of parental consent for participation in the study

Date of first enrolment

10/06/2023

Date of final enrolment

10/11/2023

Locations

Countries of recruitment

Czech Republic

Study participating centre

Motol University Hospital

V Úvalu 84/1

Prague

Czech Republic

15006

Sponsor information

Organisation

Vlček Family Foundation

Funder(s)

Funder type

Charity

Funder Name

Vlček Family Foundation

Results and Publications**Individual participant data (IPD) sharing plan**

The dataset generated and analyzed during the current study will be available upon request from Anna Zubkova (anna.zubkova1250@gmail.com)

IPD sharing plan summary

Available on request